Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

ABSTRACT:

Purpose

Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT.

Patients and methods

Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT.

Results

IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was

SUBMITTER: Cairncross JG 

PROVIDER: S-EPMC3940537 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature